Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Oteseconazole (VT-1161): Mechanistic Precision in Antifun...

    2026-04-09

    Oteseconazole (VT-1161): Mechanistic Precision in Antifungal Drug Discovery

    Introduction: The Evolving Landscape of Antifungal Therapy

    Invasive fungal infections (IFIs) represent a growing threat in both hospital and community settings, with Candida species and Cryptococcus neoformans among the leading culprits. The global rise in azole-resistant strains and complex drug-drug interaction profiles demand a new generation of selective antifungal agents. Oteseconazole (VT-1161), a potent tetrazole CYP51 inhibitor, has emerged as a paradigm-shifting compound, specifically addressing these challenges through its unique mechanism and pharmacological attributes.

    Mechanistic Insights: Lanosterol 14α-Demethylase Inhibition and Ergosterol Biosynthesis

    Targeting the Fungal CYP51 Enzyme

    Ergosterol is an essential component of fungal cell membranes, conferring structural integrity and functional viability. The biosynthesis of ergosterol is critically dependent on the activity of lanosterol 14α-demethylase (CYP51), an enzyme absent in humans but highly conserved among fungi. Inhibiting this enzyme disrupts fungal cell membrane formation, leading to cell death—a mechanism underpinning the antifungal efficacy of azole drugs.

    Oteseconazole (VT-1161) distinguishes itself as a tetrazole CYP51 inhibitor with exceptional selectivity. Unlike first- and second-generation azoles, Oteseconazole employs a tetrazole moiety to interact with the heme iron of the fungal CYP51 enzyme, achieving robust inhibition of ergosterol biosynthesis while sparing human cytochrome P450 enzymes. This selectivity is central to its safety profile, minimizing off-target effects and drug-drug interactions.

    Comparative Selectivity: Human vs. Fungal CYP Enzymes

    One of the critical limitations of earlier azole antifungals is their tendency to inhibit human CYP enzymes, particularly CYP3A4, leading to significant pharmacokinetic interactions. Oteseconazole exhibits a markedly reduced affinity for human CYP3A4 (IC50 = 65 μM), compared to much lower values for imidazole and triazole analogs. This property translates into a lower risk of adverse interactions in polypharmacy scenarios, enhancing its clinical utility for patients requiring complex treatment regimens.

    Pharmacological Profile of Oteseconazole (VT-1161)

    Potency Against Candida and Cryptococcus Species

    Oteseconazole demonstrates potent antifungal activity, with minimum inhibitory concentrations (MICs) ranging from ≤0.00625 to 0.1 μg/mL against a spectrum of Candida species, including C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, and Cryptococcus neoformans. Notably, it maintains efficacy against fluconazole-resistant Candida strains, a major clinical challenge in contemporary antifungal therapy. These findings are grounded in both in vitro and in vivo models, with typical antimicrobial testing concentrations spanning 0.00625–0.1 μg/mL.

    Limitations and Spectrum

    While Oteseconazole is largely inactive against Aspergillus fumigatus (MIC >64 μg/mL), its spectrum is highly optimized for Candida and Cryptococcus pathogens—those most frequently implicated in IFIs and recurrent vulvovaginal candidiasis (RVVC).

    Distinct Mechanism: How Tetrazole Chemistry Redefines CYP51 Inhibition

    The shift from triazole to tetrazole in Oteseconazole’s structure is not merely cosmetic. This modification enhances metabolic stability and further decreases affinity for human CYP enzymes, as elucidated in the landmark study by Luo et al. (European Journal of Medicinal Chemistry, 2025). The research underscores that the tetrazole group in Oteseconazole achieves a delicate balance between antifungal potency and reduced toxicity, a profile unattainable by most earlier azoles.

    At the molecular level, Oteseconazole’s tetrazole ring forms a strong coordinate bond with the heme iron of fungal CYP51, outcompeting endogenous lanosterol and effectively halting the ergosterol biosynthesis pathway. This results in rapid depletion of cellular ergosterol and disruption of membrane integrity—leading to cell lysis and death in susceptible fungi.

    Comparative Analysis: Oteseconazole Versus Traditional Azoles and Novel CYP51 Inhibitors

    Most existing reviews, such as "Tetrazole CYP51 Inhibition Redefined: Oteseconazole (VT-1161)", have contextualized Oteseconazole within the translational and clinical research space, emphasizing its selectivity and translational value. Building upon these works, this article provides a deeper mechanistic and pharmacological dissection, highlighting how the tetrazole scaffold fundamentally shifts the paradigm in CYP51 inhibitor design. Unlike previous content, which centers on practical guidance, our focus is on the chemical and structural innovations that underlie superior selectivity and metabolic stability.

    Moreover, while scenario-driven guides such as "Oteseconazole (VT-1161): Robust Antifungal Solutions for..." offer strategies for laboratory use, our analysis delves into the rational design principles and structure-activity relationships (SAR) that set Oteseconazole apart from both its predecessors and next-generation analogs (such as the V-series compounds cited in the 2025 reference).

    Advanced Applications in Fungal Pathogen Research and Drug Development

    Recurrent Vulvovaginal Candidiasis (RVVC) Prevention and Beyond

    RVVC is a debilitating condition affecting millions of women worldwide, with a significant subset of cases caused by fluconazole-resistant Candida species. By maintaining plasma concentrations above MIC thresholds, Oteseconazole is clinically deployed for the prevention of RVVC, offering long-term safety due to its low propensity for drug-drug interaction. Its pharmacokinetics, particularly when formulated as Oteseconazole 10 mM in DMSO for in vitro studies, allow for reproducible antifungal susceptibility assays and mechanistic research.

    Antifungal Susceptibility Assays and Mechanistic Studies

    Oteseconazole (VT-1161) is widely adopted as an antifungal agent for Candida infections in both basic and translational research. Its high selectivity profile minimizes confounding off-target effects in cell-based assays, making it a gold standard for dissecting the ergosterol biosynthesis pathway and for resistance profiling in fungal pathogen research. For experimental workflows, the compound’s stability in DMSO and ethanol (≥50 mg/mL) simplifies stock preparation and dosing in antifungal susceptibility assays.

    Expanding the Pipeline: Structure-Guided Antifungal Drug Development

    Recent advances in medicinal chemistry have leveraged the tetrazole scaffold, as exemplified by Oteseconazole, to produce next-generation CYP51 inhibitors with optimized pharmacokinetics and broad-spectrum activity. The referenced 2025 study by Luo et al. demonstrates that iterative modifications—such as tetrazole ring introduction, deuteration, and carbonyl blocking—enable the design of molecules (e.g., V23) that further broaden the activity spectrum and reduce human CYP inhibition.

    These innovations underscore the utility of Oteseconazole (and analogs) as both antifungal pharmacology probes and lead structures for antifungal drug development. The reduced toxicity toward human cell lines (e.g., SH-SY5Y, HUVEC) and the ability to prevent fungal phase transformation and biofilm formation are particularly promising for future therapeutic applications.

    Storage, Handling, and Laboratory Considerations

    For laboratory researchers, Oteseconazole BA1665 is provided as a solid (molecular weight: 527.39), highly soluble in DMSO and ethanol (≥50 mg/mL), and stable at -20°C for short-term use. These handling properties facilitate its use in high-throughput screening and mechanistic studies. It is recommended to prepare fresh solutions for each experiment to preserve compound integrity.

    APExBIO, a leading supplier of high-quality research compounds, ensures batch-to-batch consistency and reliable documentation for Oteseconazole (VT-1161), supporting rigorous antifungal research and drug discovery workflows.

    Conclusion and Future Outlook

    Oteseconazole (VT-1161) redefines the standard for selective fungal CYP51 inhibition, delivering exceptional potency against Candida and Cryptococcus species with an unparalleled safety profile. Its unique tetrazole-based mechanism, minimal inhibition of human CYP3A4, and robust efficacy against fluconazole-resistant pathogens position it as a cornerstone in antifungal drug development and research. As medicinal chemistry continues to evolve, structure-guided innovations inspired by Oteseconazole hold the promise of even broader-spectrum and safer antifungal therapeutics.

    For researchers seeking to advance the understanding of fungal pathogenesis and pioneer new therapies, Oteseconazole (VT-1161) from APExBIO offers a validated, selective, and mechanistically distinguished tool for the next generation of antifungal discovery.

    References:
    1. Luo, Z. et al. (2025). Discovery of a potent, broad-spectrum and in vivo effective deuterated tetrazole CYP51 inhibitor. European Journal of Medicinal Chemistry, 296, 117817. https://doi.org/10.1016/j.ejmech.2025.117817